Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-db55bd922aa6d7007a8fefbeb8bc2264"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-db55bd922aa6d7007a8fefbeb8bc2264"/>
<resource>
<Composition>
<id value="composition-en-db55bd922aa6d7007a8fefbeb8bc2264"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-db55bd922aa6d7007a8fefbeb8bc2264"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-db55bd922aa6d7007a8fefbeb8bc2264</b></p><a name="composition-en-db55bd922aa6d7007a8fefbeb8bc2264"> </a><a name="hccomposition-en-db55bd922aa6d7007a8fefbeb8bc2264"> </a><a name="composition-en-db55bd922aa6d7007a8fefbeb8bc2264-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1555/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - gavreto</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1555/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpdb55bd922aa6d7007a8fefbeb8bc2264"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - gavreto"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Gavreto is and what it is used for</li><li>What you need to know before you take Gavreto</li><li>How to take Gavreto</li><li>Possible side effects</li><li>How to store Gavreto</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What gavreto is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What gavreto is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Gavreto is</p><p>Gavreto is a cancer medicine that contains the active substance pralsetinib.</p><p>What Gavreto is used for</p><p>Gavreto is used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer ( NSCLC ), that presents with a specific rearrangement in a gene called rearranged during transfection (RET) if you have not been previously treated with another RET inhibitor medicine.</p><p>How Gavreto works</p><p>In patients whose cancer is due to an altered RET gene, the change in the gene causes the body to make an abnormal protein called a RET fusion protein, which can lead to uncontrolled cell growth and cancer. Gavreto blocks the action of RET fusion proteins and may help to slow or stop your lung cancer from growing. It may also help to shrink your cancer.</p><p>If you have any questions about how Gavreto works or why this medicine has been prescribed for you, please ask your doctor.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take gavreto"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take gavreto"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Gavreto</p><ul><li>if you are allergic to pralsetinib or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Gavreto.</p><ul><li>if you have a history of lung or breathing problems other than lung cancer.</li><li>if you have had high blood pressure</li><li>if you have had liver problems</li><li>if you have had bleeding problems</li><li>if you have ever had tuberculosis or if you have been in close contact with someone who has or has had tuberculosis. Your doctor may perform tests to see if you have tuberculosis</li></ul><p>Gavreto can cause side effects that you need to tell your doctor about straight away. These include:</p><ul><li>lung inflammation (pneumonitis). Gavreto may cause severe, life-threatening or fatal swelling (inflammation) of the lungs during treatment. The signs may be similar to those from your lung cancer. Tell your doctor straight away if you have any new or worsening signs including difficulty in breathing, shortness of breath, or cough with or without mucous, or fever.</li><li>high blood pressure (hypertension). Gavreto can increase the occurrence of high blood pressure. Your doctor will monitor your blood pressure before you start treatment, then after 1 week of your treatment and then as needed. If you have high blood pressure which is not well controlled with blood pressure medicines, please consult your doctor as it is important to make sure that your blood pressure is under control before starting Gavreto treatment.</li><li>liver injury (transaminase elevations). Your doctor will take blood tests before you start treatment, then every 2 weeks for the first 3 months of your treatment and then as needed. This is to check you do not have any liver problems while taking Gavreto. Tell your doctor straight away if you get any of the following signs: yellowing of your skin or the whites of your eyes, pain on the right side of your stomach area, dark urine, itchy skin, feeling less hungry than usual, nausea or vomiting, feeling tired, bleeding or bruising more easily than normal.</li><li>bleeding problems. Serious bleeding can occur during treatment with Gavreto. Tell your doctor straight away if you have any of these symptoms: are vomiting blood or vomit that looks like coffee-grounds, coughing up blood or blood clots, have pink or brown urine, red or black (looks like tar) stools, unusual bleeding or bruising of your skin, menstrual bleeding that is heavier than normal, unusual vaginal bleeding, nose bleeds that happen often, drowsiness or difficulty being awakened.</li><li>abnormal ECG. Gavreto may result in abnormal ECGs. You will have an ECG taken before and during your treatment with Gavreto. Tell your Doctor if you feel light-headed or experience palpitations as it may be a symptom of abnormal ECG.</li></ul><p>Look out for this while you are taking Gavreto. See Side effects in section 4 for more information.</p><p>Children and adolescents</p><p>Gavreto has not been studied in children or adolescents. Do not give this medicine to children or adolescents under the age of 18 years.</p><p>Other medicines and Gavreto</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Gavreto may affect the way other medicines work, and certain other medicines may affect how Gavreto works.</p><p>Tell your doctor or pharmacist before taking Gavreto if you are taking any of the following medicines:</p><p>The following medicines can increase the concentration of Gavreto in the blood:</p><ul><li>medicines used to treat AIDS/HIV (e.g. ritonavir, saquinavir)</li><li>medicines used to treat infections. These include medicines that treat fungal infections (antifungals such as ketoconazole, itraconazole, voriconazole, posaconazole) and medicines that treat certain types of bacterial infection (antibiotics such as telithromycin)</li><li>nefazodone, a medicine used to treat depression</li></ul><p>The following medicines can reduce the effectiveness of Gavreto:</p><ul><li>medicines used to stop seizures or fits (anti-epileptics such as phenytoin, carbamazepine, or phenobarbital)</li><li>medicines used to treat tuberculosis (e.g. rifampicin, rifabutin)</li><li>St. John s Wort, a herbal medicine used to treat depression</li></ul><p>Gavreto may affect the way some other medicines work, including:</p><ul><li>cyclosporine</li><li>paclitaxel</li><li>warfarin</li></ul><p>The medicines listed here may not be the only ones that could interact with Gavreto.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>Gavreto with food and drink</p><p>You should avoid drinking grapefruit juice and eating grapefruit or Seville oranges while on treatment with Gavreto.</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Contraception in females:</p><p>You should avoid becoming pregnant while taking this medicine. If you are able to have children, you must use highly effective contraception (for example, double-barrier contraception such as condom and diaphragm) while on treatment and for at least 2 weeks after stopping treatment. Gavreto may reduce the effectiveness of hormonal contraceptive methods (for example, birth control pill); therefore, hormonal contraceptives may not be considered highly effective. If hormonal contraception is unavoidable, it must be used in combination with a condom.</p><p>Contraception in males:</p><p>Males with female partners of childbearing potential must use effective contraception, including a barrier method, during treatment and for 1 week after completion of treatment.</p><p>Talk to your doctor about the right methods of contraception for you and your partner.</p><p>Pregnancy:</p><p>This medicine is not recommended for use during pregnancy unless absolutely necessary. Avoid becoming pregnant while being treated with this medicine as it may harm your unborn baby. Your doctor will discuss with you the potential risks of taking Gavreto during pregnancy.</p><p>Your doctor may check if you are pregnant before you start treatment with this medicine.</p><p>Breast-feeding:</p><p>Tell your doctor if you are breast-feeding or planning to breast-feed. It is not known if Gavreto passes into your breast milk. You should not breast-feed during treatment with this medicine and for at least 1 week after the last dose. Talk to your doctor about the best way to feed your baby during this time.</p><p>Fertility:</p><p>It is possible that this medicine could permanently affect your ability to have children. You are encouraged to talk to a doctor about saving your sperm or eggs before using Gavreto.</p><p>Driving and using machines</p><p>Gavreto may affect your ability to drive or use machines. Gavreto may cause you to feel fatigued. If this happens, you should not drive or operate heavy machinery until your symptoms resolve. Talk to your doctor about whether it is okay for you to drive or use machines.</p><p>Gavreto contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take gavreto"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take gavreto"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is 400 mg (4 capsules) taken by mouth once daily.</p><p>If you get side-effects, your doctor may change your dose, temporarily stop, or permanently stop treatment. Do not change your dose or stop taking Gavreto unless your doctor tells you to.</p><p>Gavreto is for oral use. Swallow the capsules whole with a glass of water, on an empty stomach. Do not eat for at least two hours before and at least one hour after taking Gavreto.</p><p>If you vomit after taking a dose of Gavreto, do not take an extra dose. Take your regular dose of Gavreto the next day.</p><p>If you take more Gavreto than you should</p><p>If you have accidentally taken too many capsules, talk to your doctor straight away. You may require medical attention.</p><p>If you forget to take Gavreto</p><p>If you miss a dose of Gavreto, take it as soon as you remember on the same day. Take your regular dose of Gavreto the next day.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Most serious side effects</p><p>Some side effects may be serious. Tell your doctor straight away if you get the following side effect (see also section 2):</p><ul><li>New or worsening signs of difficulty in breathing, shortness of breath, or cough with or without mucous, or fever</li><li>High blood pressure.</li><li>Yellowing of your skin or the whites of your eyes, pain on the right side of your stomach area, dark urine, itchy skin, feeling less hungry than usual, nausea or vomiting, feeling tired, bleeding or bruising more easily than normal (potential signs of liver problems).</li><li>Bleeding with symptoms such as coughing up blood</li></ul><p>Other side effects:</p><p>Tell your doctor or pharmacist if you notice any of the following side effects:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>Lung infection</li><li>Bladder infection</li><li>Blood test showing decrease in red blood cells</li><li>Blood test showing decrease in a type of white blood cells (e.g., neutrophils, lymphocytes, etc.)</li><li>Low platelet level</li><li>Blood tests showing increased or decreased amounts of blood mineral</li><li>Altered taste</li><li>Headache</li><li>Increased blood pressure</li><li>Bleeding</li><li>Lung inflammation</li><li>Cough</li><li>Shortness of breath</li><li>Constipation</li><li>Diarrhoea</li><li>Dryness affecting eyes, mouth and skin</li><li>Abdominal (belly) pain</li><li>Vomiting</li><li>Yellow skin and eyes</li><li>Rash</li><li>Bone or muscle pain</li><li>Lack of energy</li><li>Swellings (e.g. feet, ankle, face, eye, joint)</li><li>Fever</li><li>Blood tests showing altered amounts of a substance produced by the liver (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, bilirubin)</li><li>Blood test showing an increased level of an important substance used for assessing kidney function (creatinine)</li><li>Blood test showing higher amounts of an enzyme important for muscle function in your blood (creatine phosphokinase)</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>Painful swelling and sores in the mouth</li><li>Prolongation of the QT interval on your ECG</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>Tuberculosis</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store gavreto"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store gavreto"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the bottle label and outer carton after EXP . The expiry date refers to the last day of that month.</p><p>This medicine does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.</p><p>Do not use this medicine if you notice that the bottle is damaged or shows signs of tampering.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Gavreto contains</p><ul><li>The active substance is pralsetinib. Each hard capsule contains 100 mg of pralsetinib.</li><li>The other ingredients are:</li></ul><p>The capsule content contains: hypromellose, microcrystalline cellulose, pregelatinised starch, sodium hydrogen carbonate, citric acid, and magnesium stearate (see section 2 Gavreto contains sodium ).</p><p>The capsule shell contains: brilliant blue FCF (E133), hypromellose, and titanium dioxide (E171).</p><p>The printing ink contains: shellac, propylene glycol (E1520), potassium hydroxide, and titanium dioxide (E171).</p><p>What Gavreto looks like and contents of the pack</p><p>Gavreto 100 mg hard capsules are light blue, opaque hard capsules with BLU-667 printed on the capsule shell body and 100 mg on the capsule shell cap in white ink.</p><p>Gavreto is available in a plastic bottle with child-resistant closure containing 60, 90 or 120 hard capsules and a desiccant sachet. Each carton contains one bottle.</p><p>Keep the desiccant sachet in the bottle. The desiccant is a moisture absorbing material filled in a small sachet to protect the capsules from moisture. Do not swallow the desiccant.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder</p><p>Roche Registration GmbH<br/>Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>Manufacturer</p><p>Roche Pharma AG Emil-Barell-Strasse 1 79639 Grenzach-Wyhlen Germany</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien N.V. Roche S.A. T l/Tel: +32 (0) 2 525 82 Lietuva UAB Roche Lietuva<br/>Tel: +370 5 2546</p><p>: +359 2 818 44 Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien)</p><p>esk republika Roche s. r. o. Tel: +420 - 2 20382Magyarorsz g Roche (Magyarorsz g) Kft. Tel: +36 - 1 279 4Danmark Roche Pharmaceuticals A/S Tlf: +45 - 36 39 99 Malta (See Ireland)</p><p>Deutschland Roche Pharma AG Tel: +49 (0) 7624 Nederland Roche Nederland B.V. Tel: +31 (0) 348 438Eesti Roche Eesti O<br/>Tel: + 372 - 6 177 Norge Roche Norge AS Tlf: +47 - 22 78 90<br/>Roche (Hellas) A.E.<br/>: +30 210 61 66 sterreich Roche Austria GmbH Tel: +43 (0) 1 27Espa a Roche Farma S.A. Tel: +34 - 91 324 81 Polska Roche Polska Sp.z o.o. Tel: +48 - 22 345 18 88. France Roche T l: +33 (0)1 47 61 40 Portugal Roche Farmac utica Qu mica, Lda Tel: +351 - 21 425 70 Hrvatska Roche d.o.o. Tel: + 385 1 47 22 Rom nia Roche Rom nia S.R.L. Tel: +40 21 206 47 Ireland Roche Products (Ireland) Ltd. Tel: +353 (0) 1 469 0Slovenija Roche farmacevtska dru ba d.o.o. Tel: +386 - 1 360 26 sland Roche Pharmaceuticals A/S c/o Icepharma hf S mi: +354 540 8Slovensk republika Roche Slovensko, s.r.o. Tel: +421 - 2 52638Italia Roche S.p.A. Tel: +39 - 039 2Suomi/Finland Roche Oy<br/>Puh/Tel: +358 (0) 10 554<br/>. . & . : +357 - 22 76 62 Sverige Roche AB Tel: +46 (0) 8 726 1Latvija Roche Latvija SIA Tel: +371 - 6 7039United Kingdom (Northern Ireland) Roche Products (Ireland) Ltd. Tel: +44 (0) 1707 366This leaflet was last revised in.</p><p>This medicine has been given conditional approval . This means that there is more evidence to come about this medicine.</p><p>The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.</p><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpdb55bd922aa6d7007a8fefbeb8bc2264"/>
<resource>
<MedicinalProductDefinition>
<id value="mpdb55bd922aa6d7007a8fefbeb8bc2264"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpdb55bd922aa6d7007a8fefbeb8bc2264"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpdb55bd922aa6d7007a8fefbeb8bc2264</b></p><a name="mpdb55bd922aa6d7007a8fefbeb8bc2264"> </a><a name="hcmpdb55bd922aa6d7007a8fefbeb8bc2264"> </a><a name="mpdb55bd922aa6d7007a8fefbeb8bc2264-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/21/1555/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: GAVRETO 100 mg hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/21/1555/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="GAVRETO 100 mg hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
